Guided Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark L. Faupel
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5835 Peachtree Corners East Norcross GA United States of America 30092
- IPO Date
- Jan 8, 2021
- CIK
- 0000924515
- Website
- guidedinc.com
- Similar Companies
- Business
- Guided Therapeutics, Inc. is a medical technology company specializing in the development and commercialization of innovative medical devices based on patented biophotonic technology for early disease detection. The company’s main product is the LuViva Advanced Cervical Scan, a non-invasive, painless diagnostic device that instantly detects cervical cancers and precancers at the point of care by scanning the cervix with light and analyzing the reflected and fluorescent light to identify cellular and biochemical changes indicative of disease. Guided Therapeutics also develops proprietary hardware, software, and single-use disposable components associated with its LuViva system. The company operates internationally through distributor partnerships, with key markets including the United States, China, Eastern Europe, Southeast Asia, Turkey, and Indonesia. Founded in 1992 and headquartered in Peachtree Corners, Georgia, Guided Therapeutics targets healthcare providers and systems focused on improving cervical cancer screening efficacy and patient outcomes. In recent years, Guided Therapeutics has focused heavily on obtaining regulatory approvals and expanding commercial outreach. The company is conducting a clinical trial to secure FDA approval in the United States and has filed an application for approval with the Chinese National Medical Products Administration (NMPA), partnering with Yuanshuo Medical Instruments Corporation in China to support market entry. It has also expanded its international distributor network and raised capital through private placements in 2024, securing $835,000 for ongoing commercialization efforts. The company is exploring further applications of its biophotonics technology for early detection of other cancers, including esophageal and skin cancers, while prioritizing large-scale commercialization of the LuViva Advanced Cervical Scan globally. Its strategic initiatives include broadening regulatory clearances, enhancing distribution channels, and strengthening intellectual property protection through an extensive patent portfolio covering its methods and device designs. Guided Therapeutics operates within the healthcare equipment and medical device industry, serving markets worldwide with particular focus on emerging economies where access to conventional cervical cancer screening is limited. Its technologies aim to improve diagnostic accuracy, patient experience, and healthcare system efficiency. The company was formerly known as SpectRx, Inc. until its name change to Guided Therapeutics, Inc. in 2008. It maintains a small employee base and leverages distributor relationships for international sales, focusing on delivering early detection solutions that promote better clinical outcomes and reduce healthcare costs through novel, non-invasive technology.
Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review
Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
Guided Therapeutics (OTCMKTS:GTHP) Shares Down 12.7% – Time to Sell?
Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
Guided Therapeutics (OTCMKTS:GTHP) Trading 25.6% Higher – Here’s What Happened
Guided Therapeutics Provides Update on Completion of US FDA Clinical Trial
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
Guided Therapeutics Receives $100,000 from SMI's Investment Partners to Continue Commercialization Process of LuViva in China
Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables